RESUMO
Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a diverse array of therapeutic agents. Biological products have achieved a solid presence in clinical settings, and the anticipation of creating novel variants is increasing. These products predominantly encompass therapeutic proteins, nucleic acids and messenger RNA. The advancement of efficient LNP-based delivery systems for biologics that can overcome their limitations remains a highly favorable formulation strategy. Moreover, given their small size, biocompatibility, and biodegradation, LNPs can proficiently transport therapeutic moiety into the cells without significant toxicity and adverse reactions. This is especially crucial for the existing and upcoming biopharmaceuticals since large molecules as a group present several challenges that can be overcome by LNPs. This review describes the LNP technology for the delivery of biologics and summarizes the developments in the chemistry, manufacturing, and characterization of lipids used in the development of LNPs for biologics. Finally, we present a perspective on the potential opportunities and the current challenges pertaining to LNP technology.
RESUMO
INTRODUCTION: The blood brain barrier is a functional barrier allowing the entry into the brain of only essential nutrients, excluding other molecules. Its structure, although essential to keep the harmful entities out, is also a major roadblock for pharmacological treatment of brain diseases. Several alternative invasive drug delivery approaches, such as transcranial drug delivery and disruption of blood brain barrier have been explored, with limited success and several challenges. Intranasal delivery is a non-invasive methodology, which bypasses the systemic circulation, and, through the intra- and extra- neuronal pathways, provides direct brain drug delivery. Colloidal drug delivery systems, particularly lipidic nanoparticles offer several unique advantages for this goal. AREAS COVERED: This review focuses on key brain diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, and provide a detailed overview of the current lipid nanoparticle based treatment options explored thus far. The review also delves into basic preparation, challenges and evaluation methods of lipid drug delivery systems. EXPERT OPINION: Brain diseases present complex pathophysiology, in addition to the practically inaccessible brain tissues, hence according to the authors, a two-pronged approach utilizing new target discovery coupled with new drug delivery systems such as lipid carriers must be adopted.
Assuntos
Encéfalo/metabolismo , Fármacos do Sistema Nervoso Central/administração & dosagem , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas/administração & dosagem , Mucosa Nasal/efeitos dos fármacos , Doenças Neurodegenerativas/tratamento farmacológico , Administração Intranasal , Animais , Transporte Biológico , Barreira Hematoencefálica , Humanos , Lipídeos/química , Mucosa Nasal/metabolismoRESUMO
Glucocorticoids are widely prescribed in treatment of rheumatoid arthritis, asthma, systemic lupus erythematosus, lymphoid neoplasia, skin and eye inflammations. However, well-documented adverse effects offset their therapeutic advantages. In this work, novel nano-hydrogels for the sustained delivery of dexamethasone were designed to increase both bioavailability and duration of the administered drug and reducing the therapeutic dose. Hydrogels are soft materials consisting of water-swollen cross-linked polymers to which the insertion of cyclodextrin (CD) moieties adds hydrophobic drug-complexing sites. Polyamidoamines (PAAs) are biocompatible and biodegradable polymers apt to create CD moieties in hydrogels. In this work, ß or γ-CD/PAA nanogels have been developed. In vitro studies showed that a pretreatment for 24â»48 h with dexamethasone-loaded, ß-CD/PAA nanogel (nanodexa) inhibits adhesion of Jurkat cells to human umbilical vein endothelial cells (HUVEC) in conditions mimicking inflammation. This inhibitory effect was faster and higher than that displayed by free dexamethasone. Moreover, nanodexa inhibited COX-2 expression induced by PMA+A23187 in Jurkat cells after 24â»48 h incubation in the 10-8â»10-5 M concentration range, while dexamethasone was effective only at 10-5 M after 48 h treatment. Hence, the novel nanogel-dexamethasone formulation combines faster action with lower doses, suggesting the potential for being more manageable than the free drug, reducing its adverse side effects.
RESUMO
Nanosponges (NSs) are a new age branched cyclodextrin (CD) polymeric systems exhibiting tremendous potential in pharmaceutical, agro science, and biomedical applications. Over the past decade, different varieties of NS based on the type of CD and the crosslinker have been developed tailored for specific applications. NS technology has been instrumental in achieving solubilization, stabilization, sustained release, enhancement of activity, permeability enhancement, protein delivery, ocular delivery, stimuli sensitive drug release, enhancement of bioavailability, etc. There is a major explosion of research in the area of NS-aided cancer therapeutics. A wide of anticancer molecules both from a pharmacological and physicochemical perspective have been developed as NS formulations by several groups including ours. Our objective in this review is to capture a systematic and comprehensive snapshot of the state-of-the-art of NS-aided cancer therapeutics reported so far. This review will provide an ideal platform for both the formulation scientists working on new polymeric/drug development and cancer biologists/scientists to understand the current nanotechnologies in CD-based NS-aided cancer therapeutics. The scope of the review is limited to small molecules and CD-based NS. The review covers in detail the problems associated with anticancer small molecules, and the solution provided by CD-based NS specifically for camptothecin, curcumin, paclitaxel, tamoxifen, resveratrol, quercetin, oxygen-NS, temozolomide, doxorubicin, and 5-Fluorouracil. WIREs Nanomed Nanobiotechnol 2016, 8:579-601. doi: 10.1002/wnan.1384 For further resources related to this article, please visit the WIREs website.
Assuntos
Ciclodextrinas , Portadores de Fármacos , Nanomedicina/métodos , Nanoestruturas , Neoplasias/terapia , Animais , Humanos , CamundongosRESUMO
Asialo, tri-antennary oligosaccharide (NA3 glycan) is an endogenous compound, which supports proper folding of outer segment membranes, promotes normal ultrastructure, and maintains protein expression patterns of photoreceptors and Müller cells in the absence of retinal pigment epithelium support. It is a potential new therapeutic for atrophic age-related macular degeneration (AMD) and other retinal degenerative disorders. Herein, we evaluate the safety, in vitro stability, ocular pharmacokinetics and biodistribution of NA3. NA3 was injected into the vitreous of New Zealand white rabbits at two concentrations viz. 1 nM (minimum effective concentration (MEC)) and 100 nM (100XMEC) at three time points. Safety was evaluated using routine clinical and laboratory tests. Ocular pharmacokinetics and biodistribution of [(3)H]NA3 were estimated using scintillation counting in various parts of the eye, multiple peripheral organs, and plasma. Pharmacokinetic parameters were estimated by non-compartmental modeling. A 2-aminobenzamide labeling and hydrophilic interaction liquid interaction chromatography were used to assess plasma and vitreous stability. NA3 was well tolerated by the eye. The concentration of NA3 in eye tissues was in the order: vitreous > retina > sclera/choroid > aqueous humor > cornea > lens. Area under the curve (0 to infinity) (AUC∞) was the highest in the vitreous thereby providing a positive concentration gradient for NA3 to reach the retina. Half-lives in critical eye tissues ranged between 40 and 60 h. NA3 concentrations were negligible in peripheral organs. Radioactivity from [(3)H]NA3 was excreted via urine and feces. NA3 was stable at 37°C in vitreous over a minimum of 6 days, while it degraded rapidly in plasma. Collectively, these results document that NA3 shows a good safety profile and favorable ocular pharmacokinetics.
Assuntos
Polissacarídeos/uso terapêutico , Doenças Retinianas/tratamento farmacológico , Animais , Estabilidade de Medicamentos , Eletrorretinografia , Proteína Glial Fibrilar Ácida/metabolismo , Marcação In Situ das Extremidades Cortadas , Técnicas In Vitro , Pressão Intraocular , Modelos Teóricos , Polissacarídeos/efeitos adversos , Polissacarídeos/farmacocinética , Coelhos , Doenças Retinianas/fisiopatologia , Distribuição Tecidual , Tomografia de Coerência ÓpticaRESUMO
Nanosponges (NS) were synthesized by crosslinking of beta cyclodextrins with diphenyl carbonate. It is a hyper-branched polymer with an ultra high encapsulation efficiency leading to formation of colloidal systems. Dexamethasone (DEX) on the other hand is a poorly soluble drug with a poor corneal permeability. Excessive instillation of ocular suspension of dexamethasone leads to various complications thereby necessitating a novel nanotherapeutic system with greater ocular retention and permeation. This study aimed at formulating complexes of DEX with three types of beta-cyclodextrin NS obtained with different cross-linking ratio (viz. 1:2, 1:4 and 1:8 on molar basis with the cross-linker) for ocular applications. Nano-encapsulation was done by incubation-lyophilization technique to yield various formulations of Nanosponges (viz. F1:2, FI:4 and F1:8). From drug loading studies it was found that DEX was loaded in the highest amount in (NS 1:4), as much as 10% w/w as compared to 3% w/w and 5% w/w in 1:2 and 1:8 types of NS respectively. In vitro release studies showed that release of DEX was in a controlled manner for around 300 minutes. The particle sizes of the loaded NS formulations were between 350 and 660 nm with low polydispersity indices. The zeta potentials were sufficiently high (-20 to -27 mV) to obtain a stable colloidal nanosuspension. X-ray powder diffraction, differential scanning calorimetry and Fourier transform infra-red attenuated transmittance reflectance spectroscopy studies confirmed the interactions and encapsulation of DEX with NS. Transmission electron microscopy and atomic force microscopy studies confirmed its spherical colloidal nature. Ex vivo safety assessment done on bovine cornea showed no adverse reactions proving the safety of the system. Adhesion and retention properties of NS formulations were confirmed by use of 6-Coumarin as a model fluorescent marker. Corneal permeability of DEX from optimized formulations done on excised bovine cornea in corneal holders showed that the NS formulation showed higher permeability than the marketed formulation.
Assuntos
Córnea/química , Dexametasona/administração & dosagem , Dexametasona/química , Nanocápsulas/química , Nanocápsulas/ultraestrutura , Absorção , Administração Oftálmica , Animais , Bovinos , Difusão , Técnicas In Vitro , Peso Molecular , Nanocápsulas/administração & dosagem , Soluções Oftálmicas/administração & dosagem , Soluções Oftálmicas/síntese química , Tamanho da Partícula , Permeabilidade , Porosidade , Propriedades de SuperfícieRESUMO
We investigated the contributions of Tyrp1 and Gpnmb to the iris transillumination defect (TID) in five age cohorts of BXD mice. Using systems genetics, we also evaluated the role of other known pigmentation genes (PGs). Mapping studies indicate that Tyrp1 contributes to the phenotype at all ages, yet the TID maps to Gpnmb only in the oldest cohort. Composite interval mapping reveals secondary loci viz. Oca2, Myo5a, Prkcz, and Zbtb20 that modulate the phenotype in the age groups up to 10-13 months. The contributions of Tyrp1 and Gpnmb were highly significant in all age cohorts. Moreover, in young mice, all six gene candidates had substantial interactions in our model. Our model accounted for 71-88% of the explained variance of the TID phenotype across the age bins. These results demonstrate that along with Tyrp1 and Gpnmb, Oca2, Myo5a, Prkcz, and Zbtb20 modulate the TID in an age-dependent manner.
Assuntos
Proteínas do Olho/genética , Glaucoma/genética , Iris/patologia , Glicoproteínas de Membrana/genética , Oxirredutases/genética , Albinismo Oculocutâneo/genética , Algoritmos , Animais , Cruzamentos Genéticos , Modelos Animais de Doenças , Progressão da Doença , Oftalmopatias/genética , Feminino , Regulação da Expressão Gênica , Variação Genética , Genoma , Modelos Lineares , Masculino , Camundongos , Fenótipo , Pigmentação/genética , Locos de Características Quantitativas , TransiluminaçãoRESUMO
Cyclodextrin-based nanosponges (NS) are solid nanoparticles, obtained from the cross-linking of cyclodextrins that have been proposed as delivery systems for many types of drugs. Various NS derivatives are currently under investigation in order that their properties might be tuned for different applications. In this work, new carboxylated cyclodextrin-based nanosponges (Carb-NS) carrying carboxylic groups within their structure were purposely designed as novel Acyclovir carriers. TEM measurements revealed their spherical shape and size of about 400 nm. The behaviour of Carb-NS, with respect to the incorporation and delivery of Acyclovir, was compared to that of NS, previously investigated as a drug carrier. DSC, XRPD and FTIR analyses were used to investigate the two NS formulations. The results confirm the incorporation of the drug into the NS structure and NS-Acyclovir interactions. The Acyclovir loading into Carb-NS was higher than that obtained using NS, reaching about 70% (w/w). In vitro release studies showed the release kinetics of Acyclovir from Carb-NS to be prolonged in comparison with those observed with NS, with no initial burst effect. The NS uptake into cells was evaluated using fluorescent Carb-NS and revealed the nanoparticle internalisation. Enhanced antiviral activity against a clinical isolate of HSV-1 was obtained using Acyclovir loaded in Carb-NS.
Assuntos
Aciclovir/administração & dosagem , Antivirais/administração & dosagem , Portadores de Fármacos/química , Nanopartículas/química , beta-Ciclodextrinas/química , Aciclovir/química , Aciclovir/farmacologia , Animais , Antivirais/química , Antivirais/farmacologia , Ácidos Carboxílicos/química , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Reagentes de Ligações Cruzadas/química , Relação Dose-Resposta a Droga , Composição de Medicamentos , Herpesvirus Humano 1/efeitos dos fármacos , Microscopia Confocal , Microscopia Eletrônica de Transmissão , Microscopia de Fluorescência , Tamanho da Partícula , Espectroscopia de Infravermelho com Transformada de Fourier , Propriedades de Superfície , Células Vero , Ensaio de Placa ViralRESUMO
The present research work explores formulation design, critical scale-up considerations and bio-equivalence studies of soluble itraconazole (ITZ) in a tablet form using disordered drug delivery approach. Disordered system of ITZ with a lower viscosity grade of hydroxypropyl methyl cellulose (Pharmacoat 603) was developed for the first time and extensively characterised at three different stages, namely development of glass system, pellet coating and tablet compression using advanced analytical techniques. Complete molecular embedment of ITZ resulting in amorphisation was observed and found to be sustained until end of the real-time and accelerated stability studies. Developed formulation exhibited comparative in vitro dissolution profile (similarity factor>70) with reference product (Sporanox, Janssen Pharmaceutica) in simulated gastric fluid without enzymes. Formulation was scaled up in three batches (50,000 tablets/batch) with detailed validation of critical process parameters using process capability index method. Critical scale-up considerations like control of residual solvent content, effect of pellet size on dissolution, process variables in pellet coating, compressibility of coated pellets and cushioning effect required for desired compressibility were thoroughly discussed. Bioequivalence study of single dose of test and reference product in seven healthy human volunteers under fed condition exhibited significant bioequivalence with results (AUClast and AUC∞) lying between 90% confidence interval. With increase in number of subjects to 24, a significant effect on pharmacokinetic parameters of both reference as well as developed ITZ tablets was observed.
Assuntos
Antifúngicos/administração & dosagem , Sistemas de Liberação de Medicamentos , Itraconazol/administração & dosagem , Comprimidos , Antifúngicos/química , Antifúngicos/farmacocinética , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Itraconazol/química , Itraconazol/farmacocinética , Solubilidade , Espectrofotometria Ultravioleta , Equivalência TerapêuticaRESUMO
Camptothecin (CAM), a plant alkaloid and a potent antitumor agent, has a limited therapeutic utility because of its poor aqueous solubility, lactone ring instability and serious side effects. Cyclodextrin-based nanosponges (NS) are a novel class of cross-linked derivatives of cyclodextrins. They have been used to increase the solubility of poorly soluble actives, to protect the labile groups and control the release. This study aimed at formulating complexes of CAM with three types of beta-cyclodextrin NS obtained with different cross-linking ratio (viz. 1:2, 1:4 and 1:8 on molar basis with the cross-linker) to protect the lactone ring from hydrolysis and to prolong the release kinetics of CAM. Crystalline (F(1:2), F(1:4) and F(1:8)) and paracrystalline NS formulations were prepared. XRPD, DSC and FTIR studies confirmed the interactions of CAM with NS. XRPD showed that the crystallinity of CAM decreased after loading. CAM was loaded as much as 21%, 37% and 13% w/w in F(1:2), F(1:4) and F(1:8), respectively while the paracrystalline NS formulations gave a loading of about 10% w/w or lower. The particle sizes of the loaded NS formulations were between 450 and 600nm with low polydispersity indices. The zeta potentials were sufficiently high (-20 to -25mV) to obtain a stable colloidal nanosuspension. The in vitro studies indicated a slow and prolonged CAM release over a period of 24h. The NS formulations protected the lactone ring of CAM after their incubation in physiological conditions at 37 degrees C for 24h with a 80% w/w of intact lactone ring when compared to only around 20% w/w of plain CAM. The cytotoxicity studies on HT-29 cells showed that the CAM formulations were more cytotoxic than plain CAM after 24h of incubation.
Assuntos
Camptotecina/farmacologia , Morte Celular/efeitos dos fármacos , Fenômenos Químicos , Ciclodextrinas/química , Ciclodextrinas/farmacocinética , Estabilidade de Medicamentos , Nanoestruturas/química , Camptotecina/química , Camptotecina/farmacocinética , Portadores de Fármacos/síntese química , Portadores de Fármacos/farmacocinética , Composição de Medicamentos/métodos , Células HT29 , HumanosRESUMO
Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino]pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectivity. On the basis of its favorable pharmacokinetic profile and robust in vivo activity in HER1 and HER2 driven tumor models, 13 (BMS-599626) was selected as a clinical candidate for treatment of solid tumors.